Evidence map›Paper›PMID 32429634›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2020

[Flubendazole Inhibits the Proliferation of A549 and H460 Cells and Promotes Autophagy].

Tingjun Dong, Zejun Lu, Jingjiao Li, Yongzhen Liu, Juyi Wen

Open access · greenAbstract read
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Tingjun DongThe Second School of Clinical Medicine, Southern Medical University, Guangzhou 510280, China.
Zejun LuTumor Diagnosis and Treatment Center, The Sixth Medical Center of PLA General Hospital, Beijing 100048, China.
Jingjiao LiTumor Diagnosis and Treatment Center, The Sixth Medical Center of PLA General Hospital, Beijing 100048, China.
Yongzhen LiuTumor Diagnosis and Treatment Center, The Sixth Medical Center of PLA General Hospital, Beijing 100048, China.
Juyi WenThe Second School of Clinical Medicine, Southern Medical University, Guangzhou 510280, China.
Southern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFlubendazole is an anthelmintic and categorized in benzimidazole. Previous evidence indicates its suppression on proliferation of colon cancer and breast cancer cells. Our study aims to explore the effects of flubendazole on non-small cell lung cancer A549 and H460 cell lines and the underlying mechanism.

methodsCCK-8 assay was used to detect the effect of flubendazole at different concentrations on viability of both cell lines A549 and H460. We used western blot to detect the expression levels of autophagy-related proteins p62 and LC3 after flubendazole treatment. Cells were transfected with tandem fluorescent adenovirus (mRFP-GFP-LC3), and the impact of flubendazole treatment on autophagic flux were analyzed.

resultsCell viability analysis showed a dose-dependent inhibitory effect on proliferation of both A549 and H460, comparing to cells without flubendazole treating (P<0.001). Level of p62 decreased and LC3 II/I ratio increased in cells treated with 2 μmol/L flubendazole for 24 h and 48 h, compared to control groups (P<0.005). Red fluorescence signals increased in mRFP-GFP-LC3 transfected cells after flubendazole treating, suggesting an elevation in autophagic flux.

conclusionsFlubendazole may inhibit the proliferation of A549 and H460 cells and promote autophagy.

Indexed as

A549 CellsAntineoplastic AgentsAutophagyCell Line, TumorCell ProliferationCell SurvivalGrowth InhibitorsHumansLung NeoplasmsMebendazoleAntineoplastic AgentsflubendazoleGrowth InhibitorsMebendazoleAutophagyFlubendazoleLung neoplasms

Identifiers

PMID32429634
PMCPMC7260388
OpenAlexW3027167855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.